Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

TheInside2028 Dec. 5 at 10:14 AM

$RLMD she is ready and fully consolidated - break out over $5.10 - accumulate and hold!!!

0 · Reply

Iightning Dec. 5 at 6:46 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RLMD Contract: Dec 19 $2.5C Entry: 1.65 Exit: 2.13 Return: +29.15% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:35 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RLMD Contract: Dec 19 $2.5C Entry: 1.65 Exit: 2.13 Return: +29.15% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:13 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RLMD Contract: Dec 19 $2.5C Entry: 1.55 Exit: 2.12 Return: +36.84% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Gonzalo1006 Dec. 3 at 8:12 PM

$RLMD

0 · Reply

Wilburbeast69 Dec. 3 at 7:36 PM

$RLMD

0 · Reply

JohnTrack Dec. 3 at 12:50 PM

$RLMD story just went live, check link https://www.rapidticker.com/news/rlmd-relmada-therapeutics-announces-presentation-of-cfa064

0 · Reply

TheInside2028 Dec. 3 at 10:39 AM

$RLMD add this pullback -daily chart consolidation in tact. Will load here. Breakout above 5.18 to a double on volume....not a short play at all!!

0 · Reply

teaman60 Dec. 2 at 10:35 PM

$RLMD Just another penny stock scam

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:42 PM

$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥

0 · Reply

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Nov 13, 2025, 7:21 PM EST - 21 days ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 21 days ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 27 days ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 4 weeks ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 4 weeks ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 2 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 2 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 3 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 4 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 4 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 5 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 5 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 7 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 7 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 7 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 7 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 7 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 8 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 9 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 9 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 10 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 12, 2024, 6:45 PM EDT - 1 year ago

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

TheInside2028 Dec. 5 at 10:14 AM

$RLMD she is ready and fully consolidated - break out over $5.10 - accumulate and hold!!!

0 · Reply

Iightning Dec. 5 at 6:46 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RLMD Contract: Dec 19 $2.5C Entry: 1.65 Exit: 2.13 Return: +29.15% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:35 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RLMD Contract: Dec 19 $2.5C Entry: 1.65 Exit: 2.13 Return: +29.15% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:13 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RLMD Contract: Dec 19 $2.5C Entry: 1.55 Exit: 2.12 Return: +36.84% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Gonzalo1006 Dec. 3 at 8:12 PM

$RLMD

0 · Reply

Wilburbeast69 Dec. 3 at 7:36 PM

$RLMD

0 · Reply

JohnTrack Dec. 3 at 12:50 PM

$RLMD story just went live, check link https://www.rapidticker.com/news/rlmd-relmada-therapeutics-announces-presentation-of-cfa064

0 · Reply

TheInside2028 Dec. 3 at 10:39 AM

$RLMD add this pullback -daily chart consolidation in tact. Will load here. Breakout above 5.18 to a double on volume....not a short play at all!!

0 · Reply

teaman60 Dec. 2 at 10:35 PM

$RLMD Just another penny stock scam

0 · Reply

BEATOFtheMARKET Dec. 2 at 4:42 PM

$RLMD $RMBS $RMR $RNA $ROAD Undeniable Accuracy Cycle Trading Signal plugged into AI Lists 🔥

0 · Reply

Iightning Dec. 2 at 2:49 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RLMD **Contract:** Dec 19 $2.5C **Entry:** 1.75 **Exit:** 2.58 **Return:** **+47.20% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

VictorMason Dec. 1 at 6:07 PM

$RLMD finally beat the market w RLMD, bought 10,000 @ .38 sold some at 4.44 Friday, got cold feet over the weekend bought backback 4.15 today Now a run to $7 would be nice, dont know if or why it may run but 'hope springs eternal in the human heart'

0 · Reply

cornellhxy Nov. 30 at 2:19 PM

$RLMD

0 · Reply

TheInside2028 Nov. 29 at 10:32 AM

$RLMD ready for a double! Chart looks solid and stairstepping. Wait for the huge volume incoming. Load it here

0 · Reply

Iightning Nov. 26 at 5:49 AM

1ightning® Options Trade Alert (Actionable) | Buy $RLMD Dec 19 $5 Call | Enter: $0.27 Exit: $0.52 | Profit: 90.53% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:58 PM

1ightning® Options Trade Alert (Actionable) | Buy $RLMD Dec 19 $5 Call | Enter: $0.27 Exit: $0.52 | Profit: 90.53% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:52 AM

1ightning® Options Trade Alert (Actionable) | Buy $RLMD Dec 19 $5 Call | Enter: $0.27 Exit: $0.52 | Profit: 90.53% ROI | https://1ightning.com

0 · Reply

Gregorio777 Nov. 24 at 3:42 PM

$RLMD has 9 lives. Management here is pathetic, self serving incompetents. They keep getting bailed out. Its a Christmas miracle.

2 · Reply

BEATOFtheMARKET Nov. 23 at 5:24 PM

🔥 $RLMD $RMBS $RMR $RNA $ROAD

0 · Reply

Iightning Nov. 22 at 2:03 AM

1ightning® Options Trade Alert (Actionable) | Buy $RLMD Dec 19 $5 Call | Enter: $0.36 Exit: $0.64 | Profit: 76.90% ROI | https://1ightning.com

0 · Reply

mhaven2020 Nov. 21 at 3:15 PM

$RLMD closed here and $IVVD and into $SAVA for a few days.

0 · Reply

Iightning Nov. 21 at 5:26 AM

1ightning® Options Trade Alert (Actionable) | Buy $RLMD Dec 19 $5 Call | Enter: $0.36 Exit: $0.64 | Profit: 76.90% ROI | https://1ightning.com

0 · Reply

Market Cap	296.27M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	878,500
Avg Vol	1,124,134
Day's Range	N/A - N/A
Shares Out	73.33M
Stochastic %K	35%
Beta	0.74
Analysts	Sell
Price Target	$5.50